Takeda posts strong Phase 3 win for oral psoriasis drug

Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies

Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder

The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1

Agilent Technologies opens India Refurbishment Center

The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty

Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer

The combination also outperformed chemotherapy on another important secondary endpoint

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis

Merck KGaA launches ChemiSphere App to digitize lab workflows

The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences

Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses

The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion

ImmunityBio’s ANKTIVA wins EMA nod for early EU approval in hard-to-treat bladder cancer

Accenture invests in Ryght AI to revolutionize clinical trials

Ryght AI tackles these hurdles with its AI Site Twin platform

Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline

The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.